Cardiff Oncology, Inc.
CRDF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 40% | 26.4% | 7.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,064% | -9,224.2% | -10,276.2% | -7,912% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6,651.7% | -8,492% | -10,026.9% | -7,880.5% |
| EPS Diluted | -0.95 | -0.93 | -0.89 | -0.73 |
| % Growth | -2.2% | -4.5% | -21.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |